Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8784983 | Advances in Radiation Oncology | 2017 | 5 Pages |
Abstract
Patients with TNBC treated with neoadjuvant chemotherapy who have residual disease in the breast or lymph nodes at the time of surgery have significantly higher rates of locoregional failure and lower DFS compared with those with a pCR despite the use of adjuvant radiation therapy. Strategies to intensify therapy for patients with residual disease warrant further investigation.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Victor E. BS, Erin F. MD, Kaveh MD, James D. MD, Catheryn M. MD, Sharon MD, John P. MD,